Effect of Lavender syrup on COVID-19

Investigating the effect of Lavender (Lavandula angustifolia L.) syrup on improving the severity of cough in patients with definite or highly suspicious COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110907007511N4

Enrollment

Registered

2020-07-25

Start date

2020-05-16

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19. Condition 2: COVID-19. COVID-19, virus identified COVID-19, virus not identified

Interventions

Intervention 1: Intervention group: Supportive treatments related to the control of fever, pain, cough and other symptoms will be prescribed according to the common COVID-19 protocols in classical med

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years Conscious consent to participate in the study Fever greater than 38 degrees or a feeling of hot flashes with at least one clinical sign of a dry cough, 24% number of breaths per minute, headache or body aches, feeling weak and lethargic, anosmia (olfactory disturbance) or taste disturbances, nausea Seven days or less after the onset of symptoms at the first visit or relapse within 6 weeks of previous treatment Absence of respiratory distress Candidate for outpatient treatment

Exclusion criteria

Exclusion criteria: Need to be hospitalized Pregnancy and lactation Smoking Underlying heart / liver /kidney disease / high blood pressure Use other herbal medicines to control the symptoms of the disease Sensitivity to lavender

Design outcomes

Primary

Measure	Time frame
Changes in the severity of cough. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist of patient and disease characteristics, satisfaction with treatment by asking general questions, assessment of patient symptoms based on Visual Analogue Scale (10 points).;Changes in the severity of fever. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist of patient and disease characteristics, satisfaction with treatment by asking general questions, assessment of patient symptoms based on Visual Analogue Scale (10 points).;Change in the severity of shortness of breath. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist	—

Measure

Time frame

Changes in the severity of cough. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist of patient and disease characteristics, satisfaction with treatment by asking general questions, assessment of patient symptoms based on Visual Analogue Scale (10 points).;Changes in the severity of fever. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist of patient and disease characteristics, satisfaction with treatment by asking general questions, assessment of patient symptoms based on Visual Analogue Scale (10 points).;Change in the severity of shortness of breath. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Checklist

—

Secondary

Measure	Time frame
Quality of Life. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Short questionnaire 12 questions SF12.;Satisfaction with treatment. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Asking general questions.;Anxiety. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Based on the Hamilton Questionnaire.	—

Measure

Time frame

Quality of Life. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Short questionnaire 12 questions SF12.;Satisfaction with treatment. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Asking general questions.;Anxiety. Timepoint: Follow-up of patients in zero step (at the beginning of the study as a face-to-face visit), the first step (7 days after entering the study by telephone follow-up), the second step (14 days after entering the study by telephone follow-up), the third time (21 days after entering the study by telephone follow-up), the fourth time (14 days after the end of the study by telephone follow-up) and the fifth time (28 days after the end of the study by telephone follow-up). Method of measurement: Based on the Hamilton Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Marzieh Qaraati

Gorgan University of Medical Sciences

Dr.qaraati@goums.ac.ir+98 17 3245 1434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026